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MaOver the past 2 decades, there have been numerous stem cell studies focused on cardiac diseases, ranging from proof-of-
concept to phase 2 trials. This series of papers focuses on the legacy of these studies and the outlook for future treatment
of cardiac diseases with stem cell therapies. The ﬁrst section by Drs. Rosen and Myerburg is an independent review that
analyzes the basic science and translational strategies supporting the rapid advance of stem cell technology to the clinic,
the philosophies behind them, trial designs, and means for going forward that may impact favorably on progress. The
second and third sections were collected as responses to the initial section of this review. The commentary by Drs. Francis
and Cole discusses the review by Drs. Rosen and Myerburg and details how trial outcomes can be affected by noise, poor
trial design (particularly the absence of blinding), and normal human tendencies toward optimism and denial. The ﬁnal,
independent paper by Dr. Marbán takes a different perspective concerning the potential for positive impact of stem cell
research applied to heart disease and future prospects for its clinical application. (Compiled by the JACC editors) (J Am
Coll Cardiol 2014;64:922–37) © 2014 by the American College of Cardiology Foundation.TRANSLATING STEM CELL RESEARCH TO
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AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
BMMC = bone marrow–derived
mononuclear cell
CDC = cardiosphere-derived
cell
EF = ejection fraction
LVEF = left ventricular
ejection fraction
MI = myocardial infarction
MSC = mesenchymal stem cell
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rapidly to clinical application for subsets of patients,
including those with heart disease, and during the
past 2 decades, thousands of patients have been
administered various types of stem cells in clinical
cardiac disease studies ranging from proof-of-concept
to phase 2 trials. These clinical cardiac applications
have focused in part on patients for whom preventive
and conventional intervention strategies failed to
avert cellular depopulation, leading to intractable
clinical consequences. However, a far broader popu-
lation has received stem cells, including patients for
whom traditional therapies have proven effective (1),
and outcomes have been conﬂicting.
This paper is not intended as a thorough literature
review of the ﬁeld. Rather, we are analyzing the basic
science and translational strategies supporting the
rapid advance of stem cell technology to the clinic,
the philosophies behind the strategies, the positive
and negative aspects of trial designs reported, and the
means for going forward that may impact favorably
on progress. The analysis is provided in the context of
the complex scientiﬁc, clinical, ethical, and ﬁscal
considerations that are affected by this evolving ﬁeld
of interest.
THE PAST AS PROLOGUE.CARDIOVASCULAR
MORBIDITY AND MORTALITY. It is useful to consider
the emergence of stem cell therapy against the
background of the evolution of cardiovascular disease
outcomes in the past one-half century. Between the
mid-20th century and the turn of the millennium, a
major reduction in cardiovascular mortality (attrib-
utable to advances predating stem cell therapy)
occurred in the United States and elsewhere. For
example, the National Heart, Lung and Blood Insti-
tute reported a 49% reduction in age-adjusted mor-
tality from coronary heart disease between 1950 and
1998 (2). As a mortality rate adjusted for age, this
reﬂects prolongation of life expectancy and not
necessarily an equivalent absolute reduction in total
population mortality. One major contributing factor
was the dramatic transition from a 30% acute
myocardial infarction (AMI) death rate prior to coro-
nary care units, to <10% with interventional thera-
pies in the later 1990s (3), and even lower currently
(4).
The reduction in AMI deaths led to a survivor
cohort at risk for and characterized by the emergence
of an increasing population burden of chronic heart
failure. Development and reﬁnement of various heart
failure prevention and treatment strategies (none of
which depend on stem cell therapy) are reﬂected
in American Heart Association statistics revealingcontinued improvements in patient survival.
An example is the 33% fall in death rates from
heart failure and stroke between 1999 and
2009 (5). This does not argue against the
potential added value of stem cell therapy for
improving survival and quality of life. But, it
does demand that we provide solid scientiﬁc
underpinnings for incremental outcomes
being suggested to the public.
DIVERGENT OPINIONS REGARDING PRESENT
AND FUTURE DIRECTIONS. These advances,
along with the remaining challenges and
dichotomies that sometimes exist between
basic and clinical research, have led to divergent
viewpoints regarding advancement of cardiovascular
stem cell therapies into the clinic. Such viewpoints
expressed by leaders in the ﬁeld were published 10
years ago (6) and are paraphrased here:
1. “We do not.know what cell to use in any given
situation.until we do, we shouldn’t go forward
clinically;”
2. “The science of clinical stem cell trials isn’t sufﬁ-
ciently mature to warrant large-scale clinical
studies;”
3. “The stem cell literature is too internally contra-
dictory to provide a clear vision for going forward;”
4. “Patients who are dying and are desperate to live
should be availed of experimental stem cell thera-
pies;” and
5. “The ﬁeld is sufﬁciently mature that within 3-5
years, stem cells will have favorably altered the
clinical course of major cardiovascular disease” (6).
We shall now revisit these viewpoints in the
context of the clinical translation that has occurred
during the decade since they appeared and discuss
models and approaches for consideration as we move
into the next decade.
“WE DO NOT KNOW WHAT CELL TO USE.” (6).
There is substantial literature regarding stem cells
(7–10), and a number of stem cell types described in
this literature have been administered to patients.
Stem cells may be pluripotent (i.e., capable of differ-
entiating into literally any cell type in the body) or
multipotent (i.e., in lineages downstream of pluripo-
tency and destined to differentiate into more circum-
scribed mature cell populations). Pluripotent cells
include human embryonic stem cells and induced
pluripotent stem cells (7); the latter are derived from
adult cells using oncogenic or nononcogenic tran-
scription factors (11–15). Both cell types have been
reprogrammed intomature lineages, including cardiac
myocytes. Although both pluripotent cell types are
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2 studies address cardiovascular therapy. However,
induced pluripotent stem cells are providing an
experimental tool for studying human cardiovascular
disease genetics (e.g., Terrenoire et al. [18]).
Most human cardiac trials have employed multi-
potent cells—autologous or allogeneic mesenchymal
stem cells (MSCs) or bone marrow–derived mono-
nuclear cells (BMMCs) (8). Cardiospheres and c-kitþ
cells derived from subselection processes have been
obtained from cardiac tissues and administered
autologously (19,20). Skeletal myoblasts have been
studied in clinical trials, but an association with
potentially lethal arrhythmias and failure to see clear
beneﬁt has discouraged continuation (21).
A nagging concern in the stem cell ﬁeld has been
the possibility of a disastrous event, analogous to
that experienced with viral vectors employed in
the early days of gene therapy. Although it seemed
for a while that the safety of MSCs combined with
promising results from a number of trials would
preempt such an event, the recent identiﬁcation of
discrepancies in a number of clinical trials (22),
coupled with retraction of data integral to clinical
attempts at myocardial repair and regeneration (23),
is promoting reassessment of the validity of our
current knowledge base and approaches (24–26).
Investigation into data retraction issues (23–26) is
ongoing, and it would be inappropriate to speculate
on the outcome at this time. However, we hope that
the ﬁnal determinations will be made public in a
timely fashion so that the meaning of what
happened can be analyzed and the scientiﬁc and
clinical communities can learn lessons and again
move forward.
Should we admin is ter ce l l s or ce l l products? In
the early days of stem cell research, it was generally
assumed that the cells would themselves mature
and propagate to regenerate/repair tissues. Howev-
er, there are challenges (largely focused on cell fate)
to this mindset, as noted in human studies sug-
gesting that cell retention rates are low (reviewed in
Bartunek et al. [27]). Cell retention is in part inﬂu-
enced by route of administration, with conﬂicting
results reported for different routes. For example,
patients with dilated cardiomyopathy of various
etiologies given CD34þ cells by the intramyocardial
route showed better cell retention at 18 h and a
higher left ventricular ejection fraction (LVEF) at
6 months than those in whom the cells were
administered by the intracoronary route (28).
Other reports demonstrated that sites closest to
the MSC intramyocardial injection locus show
the greatest improvements in outcomes measuredthrough 1 to 1.5 years, and these appear to be
accompanied by secondary improvement in global
function (29–31).
Because we lack long-term cell retention data, it is
reasonable to ask whether stem cells and their prog-
eny actually remain where injected to repopulate a
myocyte-depleted myocardium or whether the stem
cells release products that mobilize endogenous car-
diac precursors. In some animal studies, various
types of stem cells do not long remain where
administered, but release paracrine factors that pro-
mote repair by mobilizing endogenous progenitors
(32–38). Paracrine contributors under investigation
include growth factors, cytokines, chemokines,
bioactive lipids, and microvesicles (39–42).
Conceivably, identifying the “appropriate” para-
crine factor(s) might lead to development of mole-
cules more selective, speciﬁc, safe, and effective
than transplanted stem cells, thereby suggesting
pharmacological strategies for regeneration/repair
(40). Alternatively, paracrine elements may be less
effective without the stem cell as their vehicle. In the
face of these uncertainties, a growing body of
research focuses on the physiological interactions of
native and donor cells with paracrine factors released
by stem cells (43,44). The outcomes of this work may
signiﬁcantly inﬂuence future approaches to regener-
ative therapy.
The impact of age . Stem cells from older experi-
mental animals (45) or human subjects (37–48) are not
as robust as those from the young. Changing the
environment in which stem cells of older individuals
are maintained and propagated might yield a formula
to improve their function. Absent this, allogeneic
MSCs from young donors are potential sources with
established safety (8,49). But if implanted cells
function to recruit native progenitors, progenitors
recruited in older individuals might not be as effec-
tive in healing and repair as those recruited in the
young.
To summarize, despite tests of multipotent cells
and their derivatives in a variety of animal models
and clinical settings and despite clinical studies sug-
gesting the potential of speciﬁc cells (8,19,20), not
only is the identity of the “best cell” to use in any
speciﬁc pathophysiological state still unknown, but
also the knowledge base used to validate employment
of certain cell types requires reconsideration as data
considered to be signiﬁcant are questioned and/or are
retracted (23–26). While the need for extreme caution
in study design is self-evident, careful analysis and
interpretation of data on which clinical advancement
is based are also critical to the viability of any ﬁeld of
clinical science.
Case series 
Randomized trial 
Pre-defined
study group
Cohort study 
Pre-defined
study group
Case-control study Series of cases 
Control Outcome 
Treated Outcome 
Outcome 
Outcome 
Matched
controls Event rate
Event rate
Review series of 
reported cases 
Observations; 
Hypothesis- 
generating 
Hypothesis- 
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Treated 
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FIGURE 1 Strategies to Evaluate Beneﬁts of Therapy
Clinical testing strategies range from rigidly controlled randomized trials to observational
strategies for deﬁning association, causation, clinical effects, and safety.
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ISN’T SUFFICIENTLY MATURE TO WARRANT LARGE-
SCALE CLINICAL STUDIES.” (6). The history of
cardiac stem cell (CSC) research and development
from basic laboratory to clinical application is remi-
niscent of a cottage industry. Individual laboratories
develop their own cells, approaches, and funding;
protect their intellectual property; and advance to
clinical trials as small businesses. A review of the
literature reveals methodological heterogeneity in
obtaining, standardizing, and administering cells,
as well as in enrolling, analyzing, and tracking pa-
tients. The overall effort is multicentric and hetero-
geneous, lacking uniform design and consistent
oversight (50).
L imitat ions in current knowledge impact ing CSC
tr ia l s . Clinical testing strategies range from rigidly
controlled randomized trials to observational strate-
gies for deﬁning association, causation, clinical
effects, and safety (Figure 1). Although clinical trial
design would beneﬁt from knowledge of the optimal
cell types for speciﬁc cardiac therapeutic indications,
we do not have that knowledge, nor have we been
able to catalog the potential downsides of cell
administration, the best way to prepare the cells, the
impact of trying to subselect or modify them, and the
best way to store, assay, or administer them (7,51–53).
Disease models have been created in mice, dogs, and
pigs, and observations are available from patients,
but we are still in midstream with regard to opti-
mizing therapy. It also remains unclear whether there
is a single optimal therapeutic model versus several
different models providing target-speciﬁc therapeutic
beneﬁts.
Inconsistent standards for CSC trial enrollment.
Many cardiac patients participating in stem cell trials
have had moderately-to-severely decompensated
heart failure in the post-AMI or chronic ischemic
heart disease setting (8,19,20,46). Even as data have
accumulated indicating that older patients are less
likely to beneﬁt than younger ones and that patients
with moderate decompensation beneﬁt inconsis-
tently, there are, as yet, no standardized stratiﬁcation
schemes for age or severity of left ventricular (LV)
dysfunction. Some studies enroll patients with an
ejection fraction (EF) >0.45. Although diastolic heart
failure with a preserved EF is recognized to have
increased mortality risk, it is not clear that repopu-
lation therapy would be as beneﬁcial to this category
of patients as it would be to those with low EFs due to
systolic heart failure. The pathological anatomy and
pathophysiology of heart failure clearly differ be-
tween these 2 patient categories.“THE LITERATURE IS TOO INTERNALLY CONTRA-
DICTORY TO PROVIDE A CLEAR VISION FOR GOING
FORWARD.” (6). Contrad ic t ions confronted in
rev iewing ind iv idua l c l in i ca l s tem cel l t r ia l s .
Most clinical trials of CSC therapy have administered
autologous or allogeneic bone marrow-derived cells
(8); some have used cells obtained from autologous
myocardial tissues (19,20). Means of obtaining and
administering stem cells also have differed, as have
the selection of subsets of patients to whom they
would be administered. Three recent studies using
different numbers, types, and modes of administra-
tion of cells in varied patient settings are exemplary.
We deliberately compare apples and oranges in
highlighting these trials to focus attention on the
questions that should arise when designing protocols
or when reading and interpreting the emerging
literature.
The FOCUS-CCTRN (Effect of Transendocardial
Delivery of Autologous Bone Marrow Mononuclear
Cells on Functional Capacity, Left Ventricular Func-
tion, and Perfusion in Chronic Heart Failure) trial (46)
delivered 100,000,000 autologous BMMCs in a ran-
domized, double-blinded study of 92 patients in
chronic ischemic heart failure. At 6 months, no sig-
niﬁcant impact was noted on the primary endpoints
(MVO2, LV end-systolic volume, and reversible
defect). An exploratory analysis showed a statistically
signiﬁcant, but physiologically limited, improvement
in LVEF.
CADUCEUS (CArdiosphere-Derived aUtologous
stem CElls to reverse ventricUlar dySfunction) (19,54)
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safety trial. An initial dose escalation protocol
assessed the safety of CD105þ/CD45 autologous
mononuclear cells obtained from myocardial biopsies
done 2 to 4 weeks after AMI and infused into the
infarct-related artery 1.5 to 3 months post-infarction.
Seventeen patients received 25,000,000 cells,
whereas 8 control subjects received standard therapy.
Cardiac function was unaltered, despite signiﬁcant
reductions in scar mass and increased viable heart
mass, regional contractility, and regional systolic wall
thickening. The same investigators are now recruiting
300 patients for a phase 1–2 trial using allogeneic cells
(55) rather than the autologous cells employed in
CADUCEUS.
SCIPIO (Administration of Cardiac Stem Cells in
Patients With Ischemic Cardiomyopathy) (20) was
reported as a randomized, open-label phase 1 trial in
patients with ischemic heart disease and congestive
failure undergoing coronary artery bypass grafting.
Right atrial biopsies were obtained during surgery; 4
months later, 20 patients received 1,000,000 autolo-
gous c-kitþ CSCs injected into the major vessel(s)
supplying an infarcted region. LVEF in CSC recipients
increased from 28% during control to 41% at 12
months. However, concerns regarding a preliminary
report of the SCIPIO trial (26,56) and the retraction of
a fundamental study of cardiac repair/regeneration
potential (23) whose basic research data were
reportedly “compromised” (24,25) have created un-
certainty regarding these observations. Although it is
claimed that the clinical SCIPIO data (56) are not
compromised (24,25), the issue remains under review
by the appropriate bodies and should not be pre-
judged prior to completion of the investigation.
The information presented in the previous text il-
lustrates some fundamental problems besetting stem
cell research. These problems are compounded by
confusion deriving from the diversity of approaches
and outcomes among the clinical trials. Arguably, the
ideal phase 2 clinical trial is sufﬁciently powered,
double-blinded, and randomized, with clearly deﬁned
and objectively identiﬁable primary and secondary
endpoints (57). Of the 3 cited studies, FOCUS (46) was
the only trial to achieve that standard, and it yielded
the least positive outcome. The other trials are not
directly comparable; they used different cells, modes
of administration, patient populations, and more
preliminary study designs, yet they received very
positive coverage (58).
What we are best advised to do regarding studies
like SCIPIO (20) or CADUCEUS (19) is await ﬁnal reports
while recalling the caveat that outcomes of relatively
small studies are often misleading (59). This caveat isnot unique to stem cell therapy; larger, randomized
trials in other areas of cardiovascular medicine have
not validated outcomes anticipated on the basis of
dramatic results from small studies (60–62).
In terpret ing and re interpret ing the l i terature .
An analysis of 133 reports from 49 trials provides
troubling insights into how stem cell trials are reported
and themeaning of their outcomes (22). More than 600
discrepancies were noted. In an earlier analysis of
48 reports from a single group, 200 discrepancies
were identiﬁed including “conﬂicts in recruitment
dates, criteria, sample sizes.cell counts.fractional
numbers of patients. arithmetical miscalculations,
statistical errors, suppression of signiﬁcant changes,
exaggerated descriptions of ﬁndings, possible silent
patient deletions.identical results with contradictory
sample sizes, contradictory results with identical
sample sizes.” (63). Elsewhere in the stem cell arena,
debate is in progress around similar analyses that
raised important questions (64–67). These issues
heighten our concerns about the adequacy and accu-
racy of some clinical trial design and reporting, con-
cerns that are not limited to the stem cell ﬁeld, but
are noted in a diversity of clinical trials (68).
Clinical stem cell studies: can we separate signals
from noise? On the basis of current knowledge and
the uncertainties generated as studies are questioned
or retracted, we might ask why clinical stem cell trials
should be continued, and if so, how? An afﬁrmative
response to “why” would likely cite a number of re-
ported successes, with the bar for success set rather
low in many cases. Context can be found in Ioannidis’
examination of 45 clinical research studies (59), albeit
none of them used stem cells. Although all claimed
efﬁcacy, 32% were either contradicted or their re-
ported magnitude of effect was unsubstantiated by
later studies. Ioannidis highlighted the uncertain
validity of small trials (59), a concern also applicable
to stem cell studies.
One means for dealing with concerns regarding
small trials is to perform a meta-analysis. However, it
is critical to remember that meta-analyses are not
intended to replace the determinism acquired from
adequately powered, carefully designed prospective
trials. Rather, their primary intent is to determine
whether merging data from homogeneously designed
studies with outcome signals too underpowered to
yield deﬁnitive conclusions provides a more robust
statistical outcome. Achieving such an outcome is
considered justiﬁcation for the design and execution
of larger prospective trials. To maintain meta-analytic
validity, the rules of meta-analysis include rigid
comparability in design, execution, and analysis of
the included studies. When multiple studies report
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the outcome signal, a meta-analysis may oversimplify
and lead to inappropriate conclusions. In addition, an
evaluation of properly designed meta-analyses that
led to performance of deﬁnitive trials demonstrated
that the outcomes of these trials did not recapitulate
the suggestions from the meta-analyses in 35% of the
comparisons (69).
An example is provided by a meta-analysis of
2,625 patients in 50 cardiac stem cell studies, which
include 2 study designs, 3 cell types, and a wide
range of sample sizes, cell numbers, modes of
administration, and follow-up periods (70). Subgroup
analyses indicated that the cell therapies were
associated with persistent improvements in LV
function and remodeling in cardiomyopathy and
AMI, and reduced mortality and recurrence of AMI
and stent thrombosis, with no increase in adverse
events (70). However, the positive signal sizes were
modest (e.g., the increase in LVEF and decrease in
infarct size averaged a physiologically marginal 4%).
The authors concluded that their meta-analysis
revealed signals warranting further long-term, large
clinical trials. Because the effect is durable and pro-
longed, greater increments in outcome signals may
be revealed after longer-term follow-up. That larger
long-term trials are justiﬁed might be a fair conclu-
sion for the larger studies dominating the statistics,
but not necessarily for smaller studies included in
the meta-analysis.
A different message came from a meta-analysis of
30 randomized controlled trials comprising 2,037
patients (71). BMMCs, MSCs, or other specialized cell
types were delivered by intracoronary infusion after
AMI. In the 22 BMMC trials included, there was no
signiﬁcant functional improvement, nor was there
any difference between BMMCs and other cell
types. This is consistent with a recent trial showing
that intramyocardial stem cell administration has a
better outcome than intracoronary (29), and may
explain why the meta-analysis incorporating both
administration routes met with a signiﬁcant, but
physiologically unimpressive, functional improve-
ment (70).
“PATIENTS ARE DYING AND ARE DESPERATE TO
LIVE: IN THAT SETTING THEY SHOULD BE AVAILED
OF EXPERIMENTAL STEM CELL THERAPIES.” (6).
Balanc ing pat ients with pat ience . That some
dying persons are desperate to live is an eternal
truism. It is equally obvious that people whose mor-
bidities impair quality of life may desperately seek
relief. Yet, the link between these challenges and
access to conceptually new therapies (whetherstem cell or any other experimental therapy for
life-limiting disorders) is historically complex. There
is an important distinction between data generated
from compassionate use of a new therapy that is
conceptually sound, but of unproven efﬁcacy, and
accumulation of efﬁcacy data that goes beyond proof
of concept and leads to scientiﬁcally-reliable thera-
peutic strategies. If desperate use in the guise of small
observational studies far outpaces valid randomized
clinical trials, the potential for medical/scientiﬁc
harm emerges, with potential for either over-
statement or understatement of efﬁcacy, or delayed
general acceptance of a rational therapy because of
the nature of scientiﬁc support. An example is the
16-year hiatus between the ﬁrst clinical implant of an
ICD and publication of the ﬁrst properly-controlled
trial supporting its efﬁcacy (72). Certainly, there is a
point in the development of new therapies for
extreme diseases where small initial observations are
needed; the challenge is knowing when proof of
concept should lead to prompt clinical trial designs.
Part of the problem derives from taking comfort
in our prior or current successes without fully
appreciating remaining barriers, and part is impa-
tience to move ahead aggressively on the basis of
leads that science and technology dangle before us,
before conclusive science emerges.
Paramedical inﬂuences—innovation and impatience.
Although not alone, the medical segment of society
feels a sense of urgency to advance innovation as
quickly as possible. Diverse stakeholders contribute
to this sense of urgency (8,51,73,74). At the center are
patients, who are often led to expect effective ther-
apy. They are surrounded by investigators seeking to
remain competitive by translating hypothesis into
proof; institutions focusing on recognition to sup-
port fundraising from industry, philanthropy, or
grants; federal funding agencies seeking the best
use of limited monies while answering to Congress
(and Congress to its constituencies); and corpora-
tions and investors viewing the entire system as
including a pathway to proﬁt. All are reviewed by the
media, which tell their stories with varying degrees of
accuracy.
None of these paramedical inﬂuences is inherently
bad. But if the goal is to move forward as quickly as
possible, there should be systems in place to modu-
late the interaction between these stressors and the
scientiﬁc community’s responses. For the cardiac
stem cell initiative, this goal is best addressed by
focusing on which conclusions are valid on the basis
of prior studies, and considering appropriate inves-
tigative and clinical application strategies going
forward.
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stances in which stem cell therapy is justiﬁed; but in
others, the sense of “now” should not precede the
accumulation of reliable scientiﬁc data. The obvious
distinction is between end-stage patients for whom
no other reasonable option is available versus the use
of stem cell therapy to prevent evolution of adverse
remodeling. In the former, uncontrolled observa-
tional therapy may be acceptable; for the latter, at our
current state of knowledge, uncontrolled studies are
scientiﬁc transgressions. Although it might be argued
that the myocardial substrate in end-stage and near–
end-stage patients might offer an environment hos-
tile to stem cell therapy, several trials ([20,29], and
reviewed in Telukuntla et al. [8]) suggest that pa-
tients with low ejection fractions can and do respond
well.
“THE FIELD IS SUFFICIENTLY MATURE THAT WITHIN
3 TO 5 YEARS STEM CELLS WILL HAVE FAVORABLY
ALTERED THE CLINICAL COURSE OF MAJOR CARDIO-
VASCULAR DISEASE” (6). This prediction, made 10
years ago, did not come to pass. Nor are we particu-
larly optimistic that it will happen in the next 3 to
5 years, although we acknowledge that it might.
Medicine has seen sudden surges in progress where
none might have been anticipated. But unless or until
that surge happens, the landscape we face will remain
challenging.
FACING THE CHALLENGE: MODELS FOR TRANSLATING
STEM CELL RESEARCH GOING FORWARD. Although
an overview of the potpourri of trial designs, cells,
patient numbers, disease states, modes of cell
administration, and follow-up gives conﬂicting sig-
nals, one inescapable message appears to be driving
investigators and clinicians: namely, that there may
be a needle worth pursuing within the haystack of
stem cell strategies and related complexities. Yet,
despite all we know about stem cells from pre-clinical
studies, they still represent something of a black box
in comparison with the levels of information we de-
mand before testing chemically synthesized sub-
stances in patients. Given this situation, how might
we go forward?
Back to the star t ing l ine—approach ing c l in i ca l
t r ia l s “ f rom scratch” . If we could backtrack to a
time when no clinical stem cell trials had yet been
done, we might commence with 2 broad strategies: 1)
“rebuilding” hearts acutely depopulated of myocytes,
which is happening currently in pre-clinical studies
using cardiac ﬁbrous skeletons seeded with cells to re-
establish functionally contracting hearts (75,76); and
2) using implanted cells or cells mobilized fromendogenous stores to repopulate myocytes in a
damaged heart. This is the basis of most current effort.
A next step would be basic cellular and animal
studies to identify whether speciﬁc cells and delivery
methods are appropriate for speciﬁc diseases or
whether a “one size ﬁts all” concept is rational. The
observation that human MSCs can be transplanted
allogeneically into patients without eliciting an im-
mune response (49,77,78) supports the latter ap-
proach. Whether using MSCs or other cells, it would be
important to standardize cell identiﬁcation, selection,
preparation, and administration before clinical trans-
lation. Furthermore, if, as reported (65), a noncardiac
source consistently gives rise to cardiopoietic cells,
standardization of such a source would be warranted.
Subsequent clinical testing would ﬁrst require
standardization of trial design. Beneﬁt would come
from marrying a therapy for which one has signiﬁcant
understanding with a disease for which a positive
response is likely. Initial studies could be performed
in limited numbers of patients to acquire data that
are hypothesis-generating and useful in preparing
more rigorously designed, larger clinical trials for
deﬁnitive hypothesis testing (79).
Standardization: biological activity and efﬁcacy.
Some questions raised in reviewing clinical trials
derive from lack of rigorous standards across labora-
tories for obtaining, developing, maintaining, and
assaying cell lines. Recognition of this issue promp-
ted a National Institutes of Health panel to recom-
mend establishing an MSC line or lines to serve as
reference standards (52). Regrettably, this comes at a
later than optimal time, because considerable effort
and money have been and continue to be expended
on a variety of cell lines of uncertain potential clinical
impact. In addition, by restricting focus to MSCs, the
opportunity to establish standards for other cell types
remains wanting. Finally, there is not yet a “solid
theoretical basis for using MSCs as broad therapeu-
tics” (52), leading to concern that it may be premature
to proceed with standardization (52). Nonetheless, as
cell lines are reported from multiple sources, some
basis for comparison with a standardized population
would be useful, if not essential.
Guide l ines and regulat ion . In the United States,
the Food and Drug Administration regulates stem cell
development as a therapy; counterpart regulations
exist in the European Union. The International Soci-
ety for Stem Cell Research has published detailed
recommendations in the format of a guidelines
document (80). The issue is not any lack of thoughtful
recommendations; rather, it is how they are inter-
preted and applied and how loopholes are exploited
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phase 2 trials in various ﬁelds are being examined and
approaches to trials updated (81) and enacted (82,83),
egregious efforts at circumvention continue, poten-
tially challenging adherence to existing standards for
administering untested therapies (e.g., 84–86).
Concerns about oversight and regulation also apply
to small clinical studies not subject to governmental
agency scrutiny. The International Society for Stem
Cell Research recommends: “Clinician-scientists may
provide unproven stem cell-based interventions to at
most a very small number of patients outside the
context of a formal clinical trial” (80), with a peer-
review process conducted by “appropriate experts”
to approve plans for the procedure.
One could argue that pioneering bone marrow
transplants (e.g., 87) and other medical milestones
justify unfettered access to “small numbers of pa-
tients” for investigators who have an idea they want
to translate rapidly. Two problems are evident:
1. We have accrued voluminous data showing posi-
tive and negative trends with regard to cell ther-
apy. Although we still need to have the best ideas
translated to the patient, any intent to administer
an unproven therapy to patients should be held to
the most rigorous standards of peer review by in-
dividuals who not only “have no vested interest in
the proposed procedure” (80), but who also hold to
the highest standards of patient advocacy within
the context of an Institutional Review Board (IRB).
2. Given the altered realities of the research univer-
sity (88–90) such that business considerations are
now strongly entrenched, if the individual pro-
posing a study is a leading light and/or the insti-
tution understands the potential for publicity and
funding deriving from performance of the study,
IRB members who review and rule on the request
may experience unintended pressures. In addition,
some IRB members, themselves, may have the
same apparent conﬂicts of interest that they are
empowered to address in others under certain
limited institutional circumstances (91). Although,
for most matters, this concern does not apply to
conventional institution-based IRBs, completely
independent external IRBs are a potential solu-
tion when broader institutional interests create
apparent conﬂicts.
Fac ing the future : 2 new cl in i ca l approaches .
Two recent efforts intended to move exploration of
cell therapy forward are noteworthy:
1. CCTRN (Cardiovascular Cell Therapy Research
Network) rethinks the design of phase 2 trials, withBayesian analysis considered as a means of
ongoing assessment of trial direction and outcome
(81). The FOCUS trial (46), reported by CCTRN in-
vestigators, exempliﬁes the appropriately de-
signed trial. Its physiological outcome was
marginal, not the “big bang” the ﬁeld might have
hoped for, but an accurate accounting of outcome.
2. BAMI (Effect of Intracoronary Reinfusion of Bone
Marrow-derived Mononuclear Cells on All-Cause
Mortality in AMI) is a Phase 3 safety/efﬁcacy all-
cause mortality trial enrolling 3,000 patients “to
test if the product and delivery method.can lead
to a 25% reduction in mortality” (92). BAMI relies
on intracoronary infusion of autologous bone
marrow-derived progenitors: the outcome depends
on this being “the right cell” and approach to
administration, as well as a logistically demanding
design in every step from patient selection through
cell preparation, administration, and follow-up.
I-SPY2, a different model for going forward.
This direction derives from the premise that, at least
at the outset, experimental cardiac therapy should
target those cardiac patients whose prognosis is not
far different from those with many types of cancer.
A potential model is the multicenter I-SPY2 (Investi-
gation of Serial Studies to Predict Your Therapeutic
Response With Imaging And moLecular Analysis 2)
phase 2 trial, evaluating neoadjuvant therapy deliv-
ered prior to breast cancer surgery (82,83). A
120-patient control group receives state-of-the-art
therapy, while 5 simultaneous experimental treat-
ment arms (120 patients each) are selected from
multiple proposed protocols. Those treatment regi-
mens showing “high Bayesian predictive probability
of being more effective than standard therapy” will
move forward, whereas those showing a low proba-
bility of improving efﬁcacy will be discontinued and
replaced by new drugs to be tested (82,83).
Consider the possibility of adapting the I-SPY2 trial
design strategy to the cardiovascular stem cell chal-
lenge by designating an appropriate high-risk popu-
lation, using current knowledge to identify the most
promising cardiac stem cells for this population,
and agreeing on administration and follow-up pro-
cedures. There might be 5, 10, or more different stem
cell populations suggested for inclusion. Multiple
hospitals independent of the institutions at which the
cells were identiﬁed and developed would carry out
the trial; the Bayesian analytic approach of I-SPY2
would be used. This potentially offers a more con-
sistent, accurate, and rapid path to deﬁnitive ans-
wers than has occurred to date, and (at least initially)
would require fewer patients as experimental
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jockeying among various business interests would
require resolution, I-SPY2 suggests that these can be
resolved and that the overall strategy has merit.
In going forward, it should be noted that issues
regarding cell fate await resolution (28–45,82,83).
Hence, future trials of various designs might more
consistently avail themselves of imaging techniques
to assess cell survival (28–31). Approaches such as
these may not only allow the correlation of cell sur-
vival with functional outcome, but may also enhance
prospects for personalizing therapy (28).
CONCLUSIONS. Although basic research continues,
data central to the myocardial repair/regeneration
effort have been retracted (23), while concurrently,
the clinical validation process in cardiac repair/
regeneration appears to be in danger of stalling. With
few exceptions, numerous variations on the same
study design are repeated, yielding variations on
the same outcomes but with continued expectation
of a different outcome. This situation perilously
approaches a clinical dead end. In the interest
of avoiding intrusions that do not beneﬁt pa-
tients, new approaches including more centralized
oversight, external peer review, and collabora-
tion among groups translating cell therapy are
desirable. We trust that the positive examples of
collaboration and advancement to which we have
referred (28–31,46,81–83,92) are steps in this direction.
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NOISE, OPTIMISM AND DENIAL—PERSPECTIVES
FOR RELIABLE DISCOVERY FROM STEM CELL
THERAPY, RENAL DENERVATION, AND
CARDIAC RESYNCHRONIZATION THERAPY
Darrel P. Francis, MA, Graham D. Cole, MA
“It is difﬁcult to get a man
to understand something.”
—Upton Sinclair (93)
Science is the systematic step-wise process of
replacing untrue beliefs with less untrue ones. A
clinician consulting with an individual patient has
different priorities. By blending scientiﬁc knowledge
with the human skill of expressing information
encouragingly, we help each patient achieve the best
possible outcome. Clinician-scientists, who straddle
this divide, have made substantial contributions.However, this merging of roles also has less-
recognized dangers.
Experienced clinicians integrate disparate infor-
mation to provide the best experience for patients.
We learn that some variables (such as blood pressure
and EF) vary randomly and largely meaninglessly
between visits. We may handle this milieu of uncer-
tainty by using clinical acumen to select those values
most appropriate to the overall picture: the conse-
quences for science are not a priority at the bedside.
In the previous section, Drs. Rosen and Myerburg
have provided a thought-provoking and insightful
account of the current situation and future challenges
for cell therapy. A notable challenge is the con-
trast between reported efﬁcacy in numerous un-
blinded or uncontrolled studies and high-proﬁle
neutrality in randomized, controlled, blinded condi-
tions. In the present section, we discuss 3 common
themes and suggest how readers can do better than
passively riding the rollercoaster of excitement and
disappointment.
NOISE. Although some biological variables do not
change (e.g., date of birth) and others change only
slowly and predictably (e.g., age), most change un-
predictably between 1 measurement and the next.
Cardiology is particularly vulnerable in this regard,
because heartbeats are numerous and variable in in-
tensity, responding to numerous internal ﬂuctua-
tions. For example, individual blood pressure or
heart rate values may vary widely over seconds or
minutes. On top of this are the challenges of sum-
marizing a large mass of data from a patient as a
single number (94,95). Different observers may do
this differently, which we may falsely attribute to lack
of skill on the part of the junior observer. In reality,
even experienced observers may not realize they are
doing it differently when secretly given identical data
twice (96).
Unlike drugs, which inevitably target multiple or-
gans in the body, cell therapy hinges on improving
cardiac function; thus, assessing cardiac function is
important. With relatively low event rates in patients
entering clinical trials, the number of patients
required to observe a morbidity–mortality beneﬁt
may be challengingly large for nascent therapies, and
so phase II trials with imaging endpoints are a logical
method of screening and reﬁning cell therapy tech-
nologies. Sadly, relatively little attention is placed on
ensuring that this cardiac function evaluation mini-
mizes noise and its deadly counterpart element,
namely, the bias of optimism.
OPTIMISM. Optimism drives us forward in clinical
research, but may also, paradoxically, be silently
Noisier and
Patient 1 
Patient 6 
Average 
Noisier
Optimistic
~0 ~0 
Patient 2 
Patient 3 
Patient 4 
Patient 5 
Optimistic
FIGURE 2 How the Size of Random Noise and the Presence of Bias Toward
Optimism Interact to Generate Statistically Signiﬁcant, But False-Positive, Results
Each data point is the measured improvement in a single patient of a clinical variable after
a therapy (which happens to be ineffective). Across all patients, the average change is 0,
but only if the measurements are acquired dispassionately. If, for example, 2 measure-
ments are made and the “best” is chosen (red data points), this optimism contributes a
positive bias (arrow) that may be (correctly) detected as statistically signiﬁcant even
though it is illusory. Noisier measurements are more vulnerable. Large study size
paradoxically makes the problem worse (97,98).
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to be in random directions. Clinical trials enroll mul-
tiple patients to make the random variations cancel
each other out. More patients provide more certainty
that pure random to-and-fro variation will average to
approximately 0.
The left column of Figure 2 illustrates this in 6
imaginary patients who have received an ineffec-
tive therapy. Their individual random increases and
decreases tend to average to approximately 0.
When individual patient noise is larger (second
column in Figure 2), there is still no reason for the
average result to be tilted 1 way rather than the
other. However, introducing optimism, for example,
by choosing the more favorable of 2 acquired values
for each patient (third column in Figure 2), gives
the average a directional tendency. With optimism,
greater noise produces a greater false-positive ef-
fect (fourth column in Figure 2). Statistical signiﬁ-
cance testing of pre- versus post-values will be
falsely exciting because noise-with-optimism is a
real statistically signiﬁcant increase. Unfortunately,
it is not a real beneﬁt.
Neither noise nor optimism alone can cause this
problem: it is the combination that is deadly (97,98).
Yet, they could not mislead us, even together, if we
recognized the need for a randomized controlled trial
with concealment of the allocation arm. This makes
the bias equal in both arms and therefore neutraliz-
able by calculating the net beneﬁt (99) of therapy as
the difference between the arms. The real threat is
noise and optimism combined with a third element,
denial.
DENIAL. As clinicians, we tend to accept the exis-
tence of noise and optimism in general, yet deny its
importance in our own individual research ﬁelds or
clinical practices. Almost all of thousands of congress
attendees (100) in several countries told us that if
blood pressure seemed not to have fallen after initi-
ating 1 ordinary antihypertensive tablet, they would
remeasure it, hoping for a lower value. For a therapy
widely publicized to have a very large effect, such as
30 mm Hg, the powerful expectation might limit
acceptance to only the lowest values.
When automated measurements showed a much
smaller effect, our community seemed determined to
deny that they might be more reliable. One explana-
tion offered was that drug trials had always shown
ofﬁce pressures to drop more than ambulatory pres-
sures (101). However, this is only true for unblinded
trials, that is, with ofﬁce pressures measured by staff
knowing which trial arm the patient is in. When staff
members are blinded, ofﬁce and ambulatorymeasurements show identical effect sizes (101). Thus,
the rarely discussed insight from drug trials is that,
unless protected by blinding, we cannot help over-
stating ofﬁce blood pressure reductions in the active
arm, because we are only human. When the large
blinded randomized controlled trial of renal dener-
vation found a far smaller blood pressure effect than
previous unblinded studies, the most likely explana-
tion was that blinding had prevented inadvertent
overstatement (98). Yet, expert analysis in our com-
munity professed confusion (102) “at the higher
level” and proposed one-half dozen explanations that
ignored the bias-resisting beneﬁts of blinding. This
could be a sophisticated, articulate, and expert
example of denial.
WHY IS GETTING A WRONG ANSWER HARMFUL?
First, scientists or investors relying on published
science may unknowingly embark on a futile path.
Drs. Rosen and Myerburg boldly highlight that “the
clinical validation process. appears to be in danger
of stalling.”
Second, frequent, but superﬁcial, public discus-
sion of positive results progressively entraps all
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FIGURE 3 Contributors to the 66% Symptomatic Response Widely Described for Cardiac Resynchronization Therapy
Within randomized controlled trials (RCTs), the response rate in the active arm averages 51%. Placebo control arms (which receive a device but
not cardiac resynchronization therapy pacing) show a response rate averaging 35%, indicating the incremental effect of pacing to be 16
percentage points. The control subjects in blinded trials report a better response than those in unblinded trials: we can use this to estimate the
size of the placebo effect of device implantation. The response in the unblinded controls is not due to pacing or implantation placebo, and
might be described as spontaneous improvement. Figure prepared based on data from Sohaib et al. (104).
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increasing difﬁculty countenancing the possibility
that the effect is illusory.
Third, when our entire community tacitly accepts
optimistic estimates as a convention, real scientiﬁc
progress can come to a halt.
The serious impediment to progress comes from
the differential ease of expanding the component
rectangles in Figure 3 (104). Suppose an exciting
report arises of an unblinded cohort experiencing a
high response rate (e.g., 80%). This may represent a
Nobel-prize–deserving near-doubling of the genuine
beneﬁt (red component in Figure 3) from 16% to 30%,
or a slight enlargement of the other components from
50% to 64%. Which will occur more commonly? What
innovations will thereby accumulate into the “state of
the art?” Is it, therefore, wise for our ﬁeld to deﬁne
progress by expansion of total response rate in un-
blinded, uncontrolled cohorts? The parallel in cell
therapy, elegantly highlighted by Drs. Rosen and
Myerburg, is that despite years of effort, we still do
not know which cell type to use.
The challenges are not insoluble. For example, in-
dividual patient response quantiﬁcation methods can
minimize noise (105), and automation can reduce the
bias of optimism (106). However, overcoming the
third element, denial, requires clearly contradicting
an apparent expert consensus. This can be an up-
hill struggle (107), and unfortunately, cannot be
automated.
A WAY FORWARD. There are many excellent scien-
tists working in these ﬁelds. Drs. Rosen and Myerburg
present a thoughtful, expert survey of potentialimprovements in trial design. At a more general level,
we should move forward from denial that randomi-
zation and blinding are important. We should also be
supportive of colleagues who wish to change their
public positions; otherwise we, too, are contributing
to research error.
A curious feature of cell therapy trials is that re-
ports with higher objective rates of arithmetically or
logically impossible features show more positive ef-
ﬁcacy (22). Although none of us can eradicate errors
from our work, we should prevent errors in effect size
measurement, especially the predictable bias toward
false appearance of beneﬁt.
As Drs. Rosen and Myerburg stated, to dilute the
effect of being a personal stakeholder in the intellec-
tual or academic property of 1 therapy, an efﬁcient
solution is to test several therapies. The I-SPY2 proto-
col is an excellent example. This design has not proven
popular with corporate cell therapy funders who wish
to have total control (for whatever reason), but it may
be the best way for patient volunteers to be sure they
are contributing to improvements in treatment.
Our ﬁnal proposal resolves a dilemma. Researchers
will always want to spin data favorably to obtain
employment advancement (or even merely continu-
ation), secure funding (academic or industry), or
progress on the medicopolitical society ladder. The
challenge is to allow this, but insulate ordinary sci-
entiﬁc readers seeking reliable information who
may stumble across the paper. Perhaps a code word
could be inserted for readers to recognize a paper as
not intentionally misleading but merely optimistic
marketing deserving poetic license? We suggest 3
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“emerging,” “nascent,” and “exciting.”
CELL THERAPY FOR HEART DISEASE:
A GLASS HALF FULL
Eduardo Marbán, MD, PhD
In their review of stem cell research as applied to
heart disease, Drs. Rosen andMyerburg emphasize the
dashed expectations of the last decade: the re-
tractions, the exaggerations, and the ﬁts and starts. My
own view of the status of the ﬁeld is more positive. The
path has not been linear, nor should the oft-shameful
history of cardiac cell therapy be taken as a roadmap
for scholarly translation. Nevertheless, remarkable
progress has beenmade. Indeed, in reﬂecting upon the
ﬁeld, I have identiﬁed 6 major emergent insights that
have the potential to shape future progress (108). By
way of a counterpoint to the previous section, I will
consider each of these emergent insights as tangible
examples of forward movement.
1. ESTABLISHMENT OF SAFETY WITH INTRA-
CORONARY DELIVERY. In 2001, an AMI patient was
treated by injection of autologous BMMCs down the
infarct-related artery (109). Although the scientiﬁc
basis of this human experiment was (and remains)
shaky (110,111), the paradigm has often been
repeated and collectively forms the basis for the largest
clinical experience to date with cell therapy for heart
disease. Although notable for extraordinary safety, the
experience has resulted in little by way of changes in
surrogate endpoints such as EF, scar size, or myocar-
dial perfusion (108). Importantly, manufacturing de-
tails can inﬂuence the potency of BMMCs. This may
explain why, although their safety record has proven
superior, intracoronary BMMC trial results have been
so variable (112,113). The lack of excess arrhythmias in
BMMC-treated patients (unlike earlier experiencewith
skeletal myoblasts) is particularly notable (114).
Although BMMCs are the only cell type for which large
numbers of patients are available, thus far, the general
pattern of safety with intracoronary delivery has also
held up with other cells (19,54,56).
2. DEMONSTRATION OF THERAPEUTIC REGENERATION.
Regeneration, deﬁned as “regrowth of lost or
destroyed parts or organs” (115), is often misused to
describe functional improvement or loss of scar tis-
sue. Human BMMC studies that reported reductions
in scar size (116) show only small scar mass reductions
with no reciprocal increases in living heart muscle.
Such changes may reﬂect a salutary decrease in the
extent of injury, but not regrowth of destroyedparts. However, recent results in humans with
cardiosphere-derived cells (CDCs) do give reason to
believe in the possibility of therapeutic regenera-
tion. CDCs are stem cells in that they exhibit mul-
tilineage potential and clonogenicity (117,118), but
they work through indirect mechanisms (119). The
CADUCEUS trial (19,54) tested the safety and efﬁ-
cacy of intracoronary autologous CDCs in 17 patients
with LV dysfunction and a recent myocardial
infarction (MI) (1.5 to 3 months prior), compared with
8 routine-care control subjects. The subjects who
received CDCs (but not the control subjects) experi-
enced sizable increases in the amount of viable
myocardium over 12 months of follow-up. CADUCEUS
was the ﬁrst controlled clinical trial to demonstrate
an increase in viable tissue as a result of cell therapy
(19,54). On the basis of the interpretation of
gadolinium-enhanced cardiac magnetic resonance
scans, it was concluded that cardiac regeneration had
occurred; we went on to validate this interpretation
in pigs treated with intracoronary CDCs by directly
comparing cardiac magnetic resonance imaging
with tissue histology (120). The regrowth of lost heart
muscle in response to treatment provides proof of
the concept of therapeutic regeneration (121), even
in the setting of an “irreversible” myocardial scar.
3. THE RISE OF ALLOGENEIC CELL THERAPY. The
prevalent autologous paradigm has the advantage of
avoiding immunologic rejection, but because of
patient-speciﬁc tissue harvesting, cell processing,
and quality control, it imposes signiﬁcant risk,
expense, and inﬂexibility. In addition, cell efﬁcacy
may vary with donor age and comorbidities. The use
of allogeneic cells, if safe and effective, would bypass
such limitations, enabling the generation of “off the
shelf” cell products. However, whether or not it poses
safety hazards, the risk of immune rejection may limit
effectiveness unless rejection occurs after the cells
have exerted their beneﬁcial paracrine effects
(119,122,123). Allogeneic MSCs or their precursors have
been used in various early-phase human trials of MI
and heart failure, with no safety concerns reported to
date (124). On the basis of ﬁndings that allogeneic CDC
transplantation without immunosuppression is safe,
promotes cardiac regeneration, and improves heart
function in rats (123) and pigs (120) with MI, the ALL-
STAR (Allogeneic Heart Stem Cells to Achieve Myo-
cardial Regeneration) trial of allogeneic CDCs post-MI
is currently in progress (55). The increasing recognition
that allogeneic therapy may be safe and effec-
tive reﬂects an important turning point for the ﬁeld.
4. INCREASING MECHANISTIC INSIGHTS. The ca-
nonical mechanism of stem cell therapeutics posits
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differentiate, thereby repopulating the injured heart
(125). However, despite poor retention and minimal
long-term survival of transplanted cells, cell trans-
plantation often produces beneﬁcial effects (126).
How can cells that disappear produce lasting bene-
ﬁts? Multiple lines of evidence now indicate that the
beneﬁcial effects of transplanted CDCs are mostly
indirect (119); in the extreme, allogeneic CDCs are
cleared completely within several weeks, but their
functional and structural beneﬁts persist for at least
6 months (123). Thus, long-term transplanted cell
survival is not required for sustained beneﬁt. This
appears to be true for many other nonpluripotent
cells (108,122). Much attention is being (correctly)
devoted to identifying the key factors responsible for
indirect beneﬁts; exosomes are among the contenders
(127). Whatever the mediators turn out to be, there
has been a major conceptual shift from canonical
stem cell–based mechanisms to the notion that most
clinically-applied cells work indirectly (128), opening
new prospects for next-generation cell-free products
and rationalizing the use of allogeneic cells.
5. GLIMMERS OF CLINICAL EFFICACY. The BMMC
experience has yielded little evidence of beneﬁt in
surrogate endpoints such as EF and scar size (129).
Nevertheless, it is intriguing that signiﬁcant im-
provements in clinical endpoints have been reported.
The REPAIR-AMI (Reinfusion of Enriched Progenitor
Cells and Infarct Remodeling in Acute Myocardial
Infarction) study demonstrated favorable clinical
outcomes associated with BMMC therapy, sustained
at 5 years of follow-up (130), at which time the com-
posite endpoint of death, MI, or revascularization
exhibited an odds ratio of 0.62 in favor of the BMMC-
treated group relative to placebo (p ¼ 0.03). Clinical
outcome trends in favor of BMMNC therapy have
also emerged from meta-analyses (131,132). Interest-
ingly, the greatest beneﬁts of cell therapy occur in
patients with the most extensive MI-induced damage.
For example, in the Reinfusion of Enriched Progenitor
cells And Infarct Remodeling in Acute Myocardial
Infarction (REPAIR-AMI) (133), Finnish StemCell Study
(FINCELL) (134), and REGENT (Myocardial Regenera-
tion by Intracoronary Infusion of Selected Population
of Stem Cells in Acute Myocardial Infarction) (135)
studies, the major determinant of functional recovery
after BMMC therapy was low baseline EF. This ﬁnding
suggests that cell therapy trials might beneﬁt by tar-
geting a sicker patient population (129). The increasing
recognition that BMMCs may have clinical beneﬁts,
despite little signal in terms of surrogate endpoints,
gives reason to hope that emerging cell types, withgreater effects on scar size or EF, will have even more
notable clinical beneﬁts.
6. PROGRESSION TO PHASE 2 AND 3 STUDIES. In cell
therapy (as in many other ﬁelds), larger studies often
fail to conﬁrm promising early-phase trial results (136).
Well-powered, rigorously-designed clinical trials,
focusing on hard clinical endpoints, are needed to
determine whether changes in surrogate endpoints
(e.g., scar size, ventricular volumes, and EF) translate
into increased survival and reduced morbidity (129).
Fortunately, several such trials are in progress (114),
including the phase 3 BAMI trial of BMMCs (92). The
progression from small observational studies to larger
studies focusing on clinical endpoints reﬂects gradu-
ally increasing interest in speciﬁc therapeutic candi-
dates by commercial entities. The review by Rosen and
Myerburg castigates “paramedical inﬂuences,” but
without commercial development, the potential of
the ﬁeld will never fully be clariﬁed, nor will the
wide dissemination of reliable products be possible.
CONCLUSIONS. Based on the previously mentioned
considerations, over the last several years, it is evident
that we have developed a solid basis for moving for-
ward. Blessed to date by prevalent safety, we (fortu-
itously) managed to avoid the sort of debacle that
derailed gene therapy for more than a decade (137).
The demonstration that therapeutic regeneration
can happen, in a setting where conventional wisdom
teaches that the loss of living tissue is irreversible,
catapults theﬁeld onto anewplane yet to be reachedby
anyother treatment approach.Mounting evidence that
allogeneic cells can be safe and effective is consistent
with mainstream product development paradigms.
Increasing insights into the mechanism of action of
cell therapy provide waypoints to help us set priorities
for future work on the basis of what is and is not
rational. Intriguing glimmers of clinical efﬁcacy in
trials to date, coupled with the increasing number of
advanced-phase clinical studies currently in progress,
give further reasons for cautious positivity.
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